NiCTRi(Medical expert)

Why Chemotherapy run counter to clinical expectation

 Since  American president Richard Nickson pronounced the “war on cancer” in 1970, except a small number of Th2-belonging cancer(leukemia ・・・), it’s difficult to get rid of cancer completely even by powerful Chemotherapy today. Because………

  1. Majority of the cancers exist in Th1 cellular Immunity space. (through peripheral Div treating method, only the small quantity of the chemicals can reach the Th1 cellular Immunity space, so hard to eliminate all of the cancer cells.
  2. The  chemicals almost pooling in Th2 humoral Immunity space  and cause  the immune decline on immune-subsets.

 And these days, the traditional cancer therapy (operation, Chemo, Radiation) gives priority to cancer ablation and ignores reinforce of patient’s self-Immunity. After that, it is common to see the low immunity(the commanding tower, CD4  cells Helper-T cell subset number decreases)and comes to an incompetent situation to prevent cancer metastasis and results in  a multi-metastasis. The statistic data shows the life span for patients who use anti-cancer drugs was prolonged for only 3 months than those who don’t  use them. So during the cancer treating procedure, we not only need to get rid of cancer burden, but also need to strengthen self-Immunity. 

To confirm the cancer’s location before treating↓

To confirm the cancer’s location before treating
To confirm the cancer’s location before treating

The problem of Chemo-treating way 

 Not enough chemicals can reach to Th1 cellular Immunity space

 In Th2  humoral Immunity space, polling chemical cause Immune-decline on Immune subsets

How to estimate the survival rate ?↓

How to estimate the survival rate

The balance between cancer burden and self-Immunity yield a different prognosis

The balance between cancer burden and self-Immunity yield a different prognosis

The statistic data show the self-Immunity yield a different prognosis

The statistic data show the self-Immunity yield a different prognosis

How does the NK Cell Immunotherapy work in our immunity?

How does the NK Cell Immunotherapy work in our immunity?

As the booster role on cellular (Th1)immunity (CD8↑)

As the compensator role to maintain the CD4 T-cell subset(CD4↑) .

Not only prevent cancer but also keep a good QoL, NK cell immunotherapy yield good prognosis on cancer patients.

NiCTRi Simple style
NiCTRi Simple style

We use the NiCTRi Simple style  to figure out the changes of Immune-subsets,  analyze the immune condition, and understand the effect of undergoing cancer treatment

NiCTRi Simple style

The normal & Chemo-Immune-suppression

56year-old male
Healthy elder female(94)
79year-old female


Hypothesis of the THP (CD4) feed-back regulatory system

 After one round of NK cell infusion, the immune system directs to Th1 cells; accompanying with the increased infusions, it is shown to trend to THP cell direction slowly. Therefore, by long-term NK cell immunotherapy, it is considered that the commanding tower, CD4 cells, increases. In other words, it is indicated the fact of the enhance of immunity inside bodies by NK cell immunotherapy. 


44yrs  F   Ovarian Ca.(Post operation , multiple metastasis)  who is having Chemotherapy, simultaneously with NK cell Immunotherapy show no CD4 lymphocyte number  decrease. maintain a healthy immune condition, remove the cancer burden successfully.

44yrs  F   Ovarian Ca.
44yrs  F   Ovarian Ca.

Untreated progressing  Breast Ca.(without any treatment) 55yrs.♀(The changing after 9 times NK cell Immunotherapy )

New way to evaluate Autologous NK cell Immunotherapy with a pilot volume measurement method by Lawrence H.Schwartz & B.Zhao (department of Radiology Columbia University Medical center )

Untreated progressing  Breast Ca.(without any treatment) 55yrs.♀
Untreated progressing  Breast Ca.(without any treatment) 55yrs.♀

* The FDG uptake(SUV max) of the breast tumor reduced 10.1% after NK Immunotherapy

* The maxil. lymph node diameter decreased 4.3% & volume decrease 22.3% after  NK Immunotherapy

Two Types of Hyperthermia

  • Tumor Hyperthermia (Oncothermia)  Recommend for preventing recurrence(pre-operation /post-operation and patients undergoing chemotherapy)
  • Immune Hyperthermia (Oncobooster)   Recommend for enhancing immunity (patients undergoing chemotherapy (early stage) and immune-suppressed patients)

 Hippocrates once said “Those who cannot be cured by medicine can be cured by surgery. Those who cannot be cured by surgery can be cured by fire. Those who cannot be cured by fire, they are indeed incurable.” Hyperthermia, therapy that uses elevated temperature to eliminate cancer cell, has profound effects on cells with abnormal growth. In normal cells, cooling mechanism of the vessels help lower the ascending temperature. However, in abnormal cancerous cells, the cooling mechanism is malfunctioning. In recent studies, hyperthermia is proven to kill cancer cell, with temperature of 41 degrees Celsius and above. However, when the temperature is 42.5 degrees Celsius, its power in killing cancer cell becomes stronger. Tumor hyperthermia in our clinic, also known as Oncothermia, 

is also effective in assisting efficacy of both radiotherapy and chemotherapy. It can also lessen the adverse effects of anti-cancer drugs (chemotherapeutic agents).  Oncothermia uses radio wave of  13.56MHz to target only glucose found in the cell membrane of cancer cells, so the therapy is non-invasive and has no side effects. When the cancer cells are targeted by the radio wave and heated,  it undergos the “cancer vaccine insinuate effect(⇒CD8↑)”, which activates the killer T cells to help prevent recurring cancers. The therapy not only kills cancer but also serve as a patient’s personal cancer vaccine, making it an ideal treatment for cancer. The advantages of hyperthermia is a greatly expanding in clinical treatments and the results are very promising. 

Clinical Effectiveness of Hyperthermia from statistic data

Duke University(From Pyrexar Meical)

Pre-operative Complete Remission

Pre-operative Complete Remission

  • MMC chemotherapy with Hyperthermia:  66%
  • MMC chemotherapy without Hyperthermia: 22%

The  CR rate (local tumor control ) of Complete  Remission in Breast cancer

The  CR rate (local tumor control ) of Complete  Remission in Breast cancer

  • with hyperthermia:79%
  • without hyperthermia :39%

3 yr Cumulative Survival rate of Esophageal Cancer  after Chemotherapy

3 yr Cumulative Survival rate of Esophageal Cancer  after Chemotherapy

  • with Hyperthermia: 50%
  • without Hyperthermia: 24%

12 year Overall of Ovarian cancer Survival

12 year Overall of Ovarian cancer Survival

  • with Hyperthermia:  40%
  • without Hyperthermia: 20%

5 yr Survival Rectal Cancer with Radiation

5 yr Survival Rectal Cancer with Radiation

  • with Hyperthermia:  36%
  • without Hyperthermia: 7%

Complete Remission of Neck & Head cancer

Complete Remission of Neck & Head cancer

  • with Hyperthermia:  83%
  • without Hyperthermia: 41%

5yr Overall Survival rate

  • without Hyperthermia: 53%
  • with Hyperthermia:  0%

Tumor Hyperthermia

To build a Nano-heating with13.56MHzRF-Radiofrequency current on tumor tissue

 make tumor cells’ inside-outside temperature
      differences and destroy tumor cells membrane
 lead the tumor Apoptosis 



Select the cancer and attack them
⇒ an advanced Cancer Hyperthermia

 84 yrs. Female pancreas cancer


Undergoing 4 times autologous NK cell
Immunotherapy & 8 times Hyperthermia


Tumor  abnormal FDG accumulation show negative

 68 yrs. Male lung cancer, can not be improved  by traditional cancer therapy. prognosis equation <1


Undergoing 10times Hyperthermia


Tumor  metastasis show diminishing ~ recovering tendency

Tumor Hyperthermia

Immune-Hyperthermia(Thymus Hyperthermia)  

Maintain Immunity
Relieve Chemo-side effect

Immune-Hyperthermia(Thymus Hyperthermia)







*After 8 times Hyperthermia ⇒ Granulocyte:Mono:Lymphocyte ratios improved
  Gran.↓、lympho.↑harmonize autonomic nervous system balance 

*After 8 times Hyperthermia ⇒ Immune-conning tower CD4 subset number increase
* Helper-T CD4↑=Enhance Immunity 

Integrated  Cancer   Treatment
Immune-Response Outline

International Affiliated Agency (海外関連機構)


中国(China)中山大学腫瘤医院生物治療中心(Cancer center, Sun Yat-sen University )
中国広州省広州市東風東路651号 郵編510060 (add. 651 Dong Feng Road East, Guangzhou 510060, P.R. china)
電話(Tel):020-87343173    転真(Fax)020-87343173
窓口:沈小姐(携帯86-18002296320) Contact:Amy Shen(cell phone:86-18002296320 )


Dr. Ryu (台北陽明医院脳神経外科主任劉金亮医師)
窓口:李泰興 Contact: Teddy Lee: 886-935796475 E-mail:Kuo Joanne <>


Thainakarin Hospital PCL(Bangkok Thailand)タイナカリン病院
 345, Bangna-Trad Highway KM, 3.5 Rd, Bang Na, Bang Na, Bangkok 10260
 Tel. 0-2361-2727   0-2361-2828    Fax. 0-2361-2777   0-2361-2788
 窓口:force one International
(英語)森(携帯66-819281854)          English Contact: Mori(cell phone:66-819281854 )
(タイ語)Wasanpass(携帯66-8310162005)   Thai lContact: Wasanpass(cell phone:66-819281854 )

Hong kong(香港) (English・Cantonese 英語・粤語)

Kitty Ma(

入院関連施設(日本(東京)入院治療、For hospital care in Tokyo)

聖ヶ丘病院 Hijirikaoka Hospital     東京都多摩市連光寺92-69-6
Tel. 042-338-8111    Fax. 042-338-8118

日本語窓口:軽部(携帯 08066051678)
中国語窓口:遠山(携帯 09015543756) 
English Contact: Iwasaki (cell phone:81-9027489482)